August 28, 2015
The sodium glucose co-transporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin), marketed by Boehringer Ingelheim (BI) and Eli Lilly, is the first blood-sugar lowering drug to reduce cardiovascular risks, according to top-line study results. In a global long-term PIII study, dubbed EMPA-REG OUTCOME,...read more